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Background: The risk factors for intracranial atherosclerosis are unclear but may differ from those for other 
stroke subtypes. Here, we investigated whether metabolic syndrome, an emerging risk factor for cardiovascular 
disease, is associated with intracranial atherosclerotic stroke.
Methods: Using the Adults Treatment Panel III criteria, we evaluated the components of metabolic syndrome in 
439 patients with ischemic stroke or transient ischemic attacks. The prevalence of metabolic syndrome within each 
stroke subtype was determined, and the association between intracranial atherosclerosis and metabolic syndrome 
was evaluated.
Results: Metabolic syndrome was observed more frequently in patients with intracranial atherosclerosis than in 
those with other types of stroke (P=0.003). In a multiple regression analysis, metabolic syndrome, but not 
conventional risk factors, was independently associated with intracranial atherosclerosis (P=0.016). By contrast, the 
serum level of C-reactive protein was correlated negatively with the presence of intracranial atherosclerosis. 
Intracranial atherosclerosis was most prevalent in patients with metabolic syndrome and low levels of C-reactive 
protein (P=0.024).
Conclusions: Our results indicate that metabolic syndrome is a strong independent risk factor for intracranial 
atherosclerotic stroke. Therefore, treatment of metabolic abnormalities may be an important prevention strategy for 
intracranial atherosclerotic stroke.
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INTRODUCTION
Intracranial atherosclerosis causes 8~10% of all acute 
strokes in the United States. In one Chinese study, more 
than half of patients with acute ischemic stroke had 
intracranial stenosis.
1 The risk factors for intracranial 
atherosclerosis are unclear and may differ from those for 
other stroke subtypes; they may even differ from risk 
factors for extracranial atherosclerosis.
It has been suggested that metabolic syndrome, which 
refers to a constellation of metabolic risk factors that are 
linked to insulin resistance, is associated with increased 
risk for cardiovascular disease. The guidelines in the 
Third Report of the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATP-III) 
recognized metabolic syndrome as a secondary target for 
risk-reduction therapy and defined metabolic syndrome 
as the presence of three or more of five risk 
determinants.
2 Recently, it was reported that metabolic Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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syndrome was associated with risk that was not 
accounted for entirely by traditional risk scoring 
paradigms.
3 As ischemic stroke is a heterogeneous 
condition, the impact of metabolic syndrome on 
ischemic syndrome may depend on the stroke subtype. 
In the mid 1990s, immunoassays for C-reactive 
protein (CRP), with greater sensitivity than those 
previously in routine use, revealed that increased CRP 
values, even within the range previously considered 
normal, strongly predict future coronary events. 
Recently, it is generally accepted that inflammation is 
important in plaque rupture, including an association 
between elevated CRP levels and an increased risk of 
ischemic events or high-risk unstable plaque morphology.
Our hypothesis was that metabolic syndrome is 
associated with intracranial large atherosclerotic stroke, 
as inflammation in carotid and coronary atherosclerosis. 
Therefore, we investigated the impact of metabolic 
syndrome on the development of intracranial athero-
sclerotic stroke. We also evaluated the possible 
interrelationships among metabolic syndrome, CRP level, 
and atherosclerotic stroke.
MATERIALS AND METHODS
From September 2002 to August 2004, we 
prospectively studied consecutive patients admitted to 
the Department of Neurology at Ajou University Hospital 
with ischemic stroke or transient ischemic attacks. 
Patients were evaluated according to a protocol that 
included demographic data, medical history, vascular 
risk factors, clinical stroke syndrome, and the National 
Institutes of Health Stroke Scale (NIHSS) score, as in 
our previous studies.
4-5 All patients underwent diagnostic 
testing that included a vascular study (digital subtraction 
or magnetic resonance angiography), echocardiogram, 
electrocardiogram, and routine blood tests. Digital 
subtraction angiography was performed in 77 patients 
and magnetic resonance angiography in the remaining 
patients, at 1.8±2.3 days after the onset of symptoms. 
We additionally performed transesophageal echocardio-
gram and/or Holter monitoring, if the patient had one of 
the following characteristics: past vascular events, such 
as deep venous thrombosis, or pulmonary embolism; 
palpitations preceding or accompanying stroke onset; or 
peripheral vascular insufficiency, deep vein thrombosis, 
or pulmonary embolism (38 patients). Hemostatic 
markers of prothrombotic tendency, including protein C, 
protein S, antithrombin III, and antiphospholipid 
antibodies were measured in all patients younger than 50 
years.
Based on clinical syndrome, infarct size on a 
diffusion-weighted image, the results of vascular and 
cardiological studies, and laboratory data, we divided the 
patients into five groups, as reported previously
6: (1) 
large artery atherosclerosis (LAA); (2) cardioembolism; 
(3) small arterial disease (SAD); (4) other determined 
causes, such as carotid or vertebral dissection, hyper-
coagulable state, vasculitis, and complicated migraine; 
and (5) cryptogenic stroke. Patients in the LAA group 
were divided further into two groups: (1) those with 
occlusive lesions on the extracranial arterial system 
(EC-LAA group) and (2) those with occlusive lesions on 
the proximal portion of the middle cerebral artery, 
intracranial portion of the vertebral artery, or basilar 
artery, but with no significant stenosis on the relevant 
extracranial arterial system (IC-LAA group). An 
occlusive lesion was defined according to previously 
published criteria as >50% stenosis or occlusion of the 
large intracranial and extracranial vessels.
7-8 An 
acceptable level of agreement for the presence of an 
occlusive lesion on angiography was found between the 
raters who interpreted the angiograms (kappa=0.91, 
P<0.05). The exclusion criteria included patients who 
underwent an incomplete workup (29 patients), who had 
had two or more causes of stroke (nine patients), or who 
had isolated lesions on the intracranial portion of the 
internal carotid artery (20 patients).
The NCEP ATP-III guidelines define metabolic 
syndrome as the presence of three or more of the 
following risk factors
2: (1) abdominal obesity; (2) 
elevated triglyceride levels (≥150 mg/dl); (3) low 
high-density lipoprotein (HDL) cholesterol levels (<40 
mg/dl for men, <50 mg/dl for women); (4) hypertension 
(systolic blood pressure ≥130 mmHg or diastolic 
pressure  ≥85 mmHg) or antihypertensive medication 
use; and (5) impaired fasting glucose levels (≥110 Bang OY, et al. Metabolic Syndrome, CRP, Intracranial Atherosclerosis 
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Metabolic syndrome
P
Absent Present
No. of patients 240 (55.3%) 199 (43.3%)
Epidemiological data
Age (years)
Male sex
60.8±13.6
156 (65.0%)
64.0±10.2
98 (49.2%)
0.006
0.001
Severity of stroke
NIHSS score 5.2±4.8 3.1±3.7 <0.001
Stroke syndrome
Total anterior
Partial anterior
Posterior circulation
Lacunar
Transient ischemic attack
81
17
41
74
27
43
29
37
72
18
0.026
Table 1. General characteristics of the study population mg/dl). Using the revised Asia-Pacific criteria suggested 
by the World Health Organization Western Pacific 
Region (2000), abdominal obesity was defined as a waist 
circumference of ≥90 cm for men and ≥80 cm for 
women.
9
Samples of peripheral blood were withdrawn from 
each patient at the time of admission (mean±SD=1.8±2.2 
days after symptom onset). As a novel risk factor for 
atherosclerosis, the serum levels of CRP of all except 
eight patients were evaluated using a highly sensitive 
assay. Three patients with CRP levels >100 mg/L were 
also excluded from this assay because of the possible 
coexistence of an infectious condition. Consistent with 
recent recommendations from the Centers for Disease 
Control and Prevention, a CRP cutoff value of 3 mg/L 
was used to differentiate high and low levels.
10
Differences between groups were examined using a 
Chi-squared test, Student’s t-test, or a one-way analysis 
of variance (ANOVA) with appropriate post hoc tests 
for significance. We performed a multi-variant logistic 
regression analysis to determine whether metabolic 
syndrome and CRP levels were independent predictors 
for intracranial atherosclerosis in addition to the risk 
factors for stroke. Those factors that were significant at 
the 0.2 level were entered into the initial multivariate 
model. When the most parsimonious model was obtained 
by backward stepwise elimination of nonsignificant 
factors, each of the excluded variables was again entered 
separately into the model to test its contribution to the 
final model. The results are presented as odds ratio (OR) 
estimates of relative risk with a 95% confidence interval 
(CI). Statistical significance was established at P<0.05.
RESULTS
Among 497 patients who were admitted during the 
study period, 439 were included in the study (254 men 
and 185 women, mean age=62.3±12.3 years). According 
to clinical, diffusion-weighted imaging, angiography, and 
cardiological findings, 121 patients were classified in the 
IC-LAA group, 67 in the EC-LAA group, 104 in the 
SAD group, 56 in the cryptogenic group, 60 in the 
cardioembolic group, and 31 in the other cause group.
The clinical characteristics are presented in Table 1. 
Metabolic syndrome was observed in 199 of 439 
patients (43.3%). Patients with metabolic syndrome were 
significantly older and were more likely to be female (P 
=0.05 for both variables). The severity of stroke and 
stroke syndrome differed according to the presence of 
metabolic syndrome: the NIHSS score at admission was 
significantly lower in patients with metabolic syndrome 
than in those without metabolic syndrome (P<0.001), 
and, while total anterior circulation infarcts were more 
common in the latter group, lacunar and partial anterior 
circulation infarcts were observed more often in the 
former group (P=0.026).
The frequency of metabolic syndrome was variable 
and depended on the stroke subtype (P=0.003). Patients 
in the IC-LAA group had the highest frequency of 
metabolic syndrome (58.7%), whereas lower frequencies 
of metabolic syndrome were associated with patients 
with cardioembolic (30.0%), cryptogenic (35.7%), and 
other types of stroke (35.5%). The prevalence of 
metabolic syndrome in patients in the SAD and 
EC-LAA groups was similar and intermediate (48.1 and 
43.3%, respectively). The same was true for the number 
of components of metabolic syndrome exhibited by 
patients (P<0.001; Fig. 1): patients in the IC-LAA group 
had a higher level of metabolic abnormality compared Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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Stroke subtype
P
Intracranial atherosclerosis Other
Presence of metabolic syndrome
No. of components, mean±SD
60 (56.6%)
2.70±1.23 
139 (41.7%)
2.17±1.37
0.007
<0.001
Individual components
Blood pressure ≥130/85 mmHg
Fasting glucose >110 mg/dl
Waist circumference 
M >90 cm, F >80 cm
Serum triglyceride >150 mg/dl 
Serum HDL-cholesterol, 
M <40 mg/dl, F <50 mg/dl
72 (67.9%)
49 (46.2%)
65 (61.3%)
44 (41.9%)
58 (55.2%)
182 (53.4%)
142 (42.0%)
148 (43.4%)
119 (35.3%)
141 (41.7%)
0.008
0.405
0.001
0.221
0.015
M; male, F; female, HDL; high-density lipoprotein
Table 2. Frequencies of individual components of metabolic syndrome depend on the presence of intracranial atherosclerosis
Fig. 1. The number of components of metabolic syndrome 
within each stroke subtype. Asterisk indicates a significantly 
higher value compared with other stroke subtypes (P<0.001). 
SAD; small arterial disease, EC-LAA; extracranial large arterial
atherosclerosis, IC-LAA; intracranial large arterial atherosclerosis
with those of the other groups, particularly with regard 
to blood pressure, abdominal obesity, and HDL 
cholesterol levels (Table 2).
Table 3 shows the results of the multiple logistic 
regression model and the OR for each factor. Metabolic 
syndrome, but not conventional risk factors, was 
independently associated with intracranial athero
Variables
Intracranial atherosclerosis
OR (95% CI) P
Age
Male sex
Hypertension
Diabetes
Smoking
LDL-cholesterol, mg/dl
Previous stroke history
Previous CAOD history 
-
-
-
-
-
-
-
-
0.515
0.516
0.295
0.429
0.521
0.109
0.597
0.498
Metabolic syndrome, 
No. of component
One component
Two components
Three components
Four components
Five components
3.131 (0.867-11.303)*
4.374 (1.247-15.332)*
5.157 (1.479-17.976)*
7.581 (2.140-26.853)*
5.383 (1.131-25.633)*
0.016
0.082
0.021
0.010
0.002
0.035
C-reactive protein, mg/L 0.725 (0.504-1.044) 0.084
LDL; low-density lipoprotein, CAOD; coronary artery occlusive 
disease. *Compared with patients with no components of 
metabolic syndrome.
Table 3. Multiple regression analysis
sclerosis. Patients with more severe metabolic abnor-
malities were more likely to have intracranial athero-
sclerosis (P=0.016). Patients with 1, 2, 3, 4, and 5 
components of metabolic syndrome were about 3, 4, 5, Bang OY, et al. Metabolic Syndrome, CRP, Intracranial Atherosclerosis 
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Figure 2. The impact of metabolic syndrome and C-reactive 
protein levels on atherosclerotic stroke. Filled bars (■), 
intracranial atherosclerosis; Open bars (□), extracranial 
atherosclerosis. Met SD indicates metabolic syndrome. CRP, 
C-reactive protein. Low and high refers to CRP levels of ≤3 and
>3 mg/L, respectively.
8, and 5 times more likely to have intracranial athero-
sclerosis, respectively, compared with patients who had 
no abnormalities, after adjustment for other risk factors. 
By contrast, CRP levels were correlated negatively with 
intracranial atherosclerosis, although this correlation was 
not statistically significant (P=0.084).
To explore the relationships among metabolic 
syndrome, CRP level, and intra- and extracranial 
atherosclerosis, we divided the study cohort into four 
groups on the basis of the presence or absence of 
metabolic syndrome and on the basis of CRP levels less 
than or greater than 3.0 mg/L. As shown in Fig. 2, the 
frequency and type of atherosclerotic stroke were 
associated with the serum level of CRP as well as with 
the presence or absence of metabolic syndrome. When 
the patients were categorized into four risk groups, 
strokes in patients in the IC-LAA group were less 
prevalent in patients who had a high level of serum CRP 
than in patients with a low CRP level, regardless of the 
presence or absence of metabolic syndrome. The 
frequency of intracranial atherosclerosis was highest in 
patients who had metabolic syndrome and low CRP 
levels and was lowest in patients who had metabolic 
syndrome and high CRP levels (P=0.024). The latter 
group had the highest frequency of extracranial 
atherosclerosis, although this was not statistically 
significant (P=0.262). Beside the site of atherosclerosis, 
the level of CRP was not related to the presence or 
absence of metabolic syndrome (4.60±9.25 mg/L and 
4.42±9.54 mg/L, respectively; P=0.845). In addition, for 
all subjects, correlation analysis showed that CRP was 
not significantly associated with blood pressure, serum 
glucose, triglyceride, HDL-cholesterol, and waist 
circumference (r<0.05, P>0.05 in all the cases).
DISCUSSION
Metabolic syndrome is associated with an increased 
risk of cardiovascular disease and mortality in patients 
without a history of cardiovascular disease. Metabolic 
syndrome is also associated with subclinical ultrasound- 
associated atherosclerosis.
11 In the present study, the 
proportion of individuals with metabolic syndrome was 
almost identical to those evaluated in other studies of 
stroke patients; specifically, the proportion of patients in 
the present study with three or more components of the 
metabolic syndrome was 43.3% compared with 42.8% in 
the Second Manifestations of Arterial Disease (SMART) 
Study.
12
The apparent differences in risk factors for intra- and 
extracranial atherosclerosis are unclear. In the present 
study, we investigated several novel factors that emerged 
recently as risk factors for atherosclerosis. Our study 
revealed diversity in the frequency of metabolic 
syndrome that depended on the stroke subtype; this may 
be due to the fact that ischemic stroke is a hetero-
geneous condition. Our study revealed that metabolic 
syndrome (rather than conventional risk factors) is a 
strong independent risk factor for intracranial 
atherosclerotic stroke. To our knowledge, the frequency 
and implications of metabolic syndrome in patients with 
intracranial atherosclerosis have not been reported to 
date. The association between intracranial atherosclerosis 
and metabolic syndrome may be derived from the 
individual components of the syndrome, such as 
abdominal obesity, hypertension, and HDL cholesterol 
levels. However, our multivariate analysis demonstrated 
that modeling the severity of metabolic abnormalities as 
a risk factor for intracranial atherosclerosis was a Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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powerful yet convenient method to incorporate several 
proven risk factors.
Why did patients with intracranial atherosclerosis in 
the present study exhibit a high frequency of metabolic 
syndrome? Possible explanations for this include the 
followings. First, oxidative stress is associated with 
metabolic syndrome and has been suggested to play a 
role in endothelial dysfunction and subsequent 
atherosclerosis.
13 Increased vascular risk may be 
explained by the individual risk factors of metabolic 
syndrome in association with other aspects of the 
syndrome that are not measured routinely, such as 
oxidative stress, impaired fibrinolysis, increased small 
dense low-density lipoprotein (LDL) cholesterol levels, 
hypercoagulability, inflammation, and hyperinsulinemia.
14 
The Third National Health and Nutrition Examination 
Survey reported that adults with metabolic syndrome 
have suboptimal concentrations of several antioxidants, 
which may explain in part why such individuals are at 
greater risk for the development of cardiovascular 
disease.
15 An autopsy study revealed that intracranial 
arteries responded with accelerated atherogenesis when 
antioxidant protection of these arteries was decreased to 
a relatively greater extent than was the case for 
extracranial arteries.
16 The authors suggested that the 
progression of atherosclerosis within intracranial arteries 
might be due partly to reduced intracellular defenses 
against oxygen radical-mediated processes. Therefore, it 
is conceivable that intracranial arteries become suscep-
tible to oxidative stress resulting in atherosclerotic 
stroke, particularly under conditions of increased 
oxidative stress such as those that exist in patients with 
metabolic syndrome. Further studies of markers of 
oxidative stress in patients with intracranial athero-
sclerosis are needed. The second explanation of why 
patients with intracranial atherosclerosis exhibited a high 
frequency of metabolic syndrome is that atherogenesis 
(including the effect of plasma lipids
17) within the 
intracranial vascular bed might be different from 
atherogenesis that occurs in coronary or extracranial 
carotid arteries. Hemodynamic conditions affect athero-
genesis and might modify the effects of circulating 
agents in different vascular beds.
Recently, it was reported that CRP levels were greater 
in patients with metabolic syndrome and that CRP 
provided important and independent prognostic 
information about further cardiovascular risk.
18-19 It is 
well known that CRP directly affects vessel walls and 
that inflammation is important in plaque rupture. In the 
present study, however, the level of CRP was negatively 
correlated with the presence of intracranial athero-
sclerosis, regardless of the presence or absence of 
metabolic syndrome. In the same manner, extracranial 
atherosclerosis was observed most frequently in patients 
that did not have metabolic syndrome and also had 
increased CRP levels. These findings suggest that the 
mechanisms that underlie the development of 
atherosclerosis within intracranial arteries may differ 
from those that occur within extracranial arteries and 
that pathophysiological mechanisms other than 
inflammation may play an important role in the 
development of intracranial atherosclerosis.
A limitation of the present study is that our results 
may represent stroke patients with a high prevalence for 
intracranial atherosclerosis. However, confounding 
factors such as differences in the prevalence of risk 
factors and genetic background were precluded. The 
strengths of our study include the prospective study 
design and the availability of well-characterized stroke 
events for analysis (stroke subtypes, and conventional 
and novel risk factors). We believe that further studies 
of different populations (e.g., Caucasians) and larger 
cohorts are warranted.
The results of the present study suggest that a 
different therapeutic approach may be needed for 
atherosclerotic stroke and that the diagnosis of metabolic 
syndrome (and possibly measurements of CRP levels) 
will be useful in targeting therapies for the primary 
prevention of atherosclerotic stroke. If the results of the 
present study are replicated in subsequent studies, we 
propose that pharmacological or nonpharmacological 
treatment of the metabolic abnormalities that characterize 
the metabolic syndrome may be a major new strategy 
for preventing intracranial atherosclerotic stroke.Bang OY, et al. Metabolic Syndrome, CRP, Intracranial Atherosclerosis 
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